Matching articles for "Aerius"

Treatment of Allergic Rhinitis and Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • March 31, 2025;  (Issue 1725)
Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table...
Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2025 Mar 31;67(1725):49-56 | Show Full IntroductionHide Full Introduction

Drugs for Allergic Rhinitis and Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • April 19, 2021;  (Issue 1622)
The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table...
The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2021 Apr 19;63(1622):57-64 | Show Full IntroductionHide Full Introduction

Intravenous Cetirizine (Quzyttir) for Acute Urticaria

   
The Medical Letter on Drugs and Therapeutics • April 6, 2020;  (Issue 1595)
Quzyttir (TerSera), an IV formulation of the second-generation H1-antihistamine cetirizine, has been approved by the FDA for treatment of acute urticaria in patients ≥6 months old. Oral formulations of...
Quzyttir (TerSera), an IV formulation of the second-generation H1-antihistamine cetirizine, has been approved by the FDA for treatment of acute urticaria in patients ≥6 months old. Oral formulations of cetirizine (Zyrtec, and others) have been for sale over the counter for years. Quzyttir is the first parenteral formulation of a second-generation H1-antihistamine to become available in the US; parenteral formulations of two first-generation H1-antihistamines, diphenhydramine (Benadryl, and others) and hydroxyzine (Vistaril, and others), have been available for many years.
Med Lett Drugs Ther. 2020 Apr 6;62(1595):55-6 | Show Full IntroductionHide Full Introduction

OTC Drugs for Seasonal Allergies

   
The Medical Letter on Drugs and Therapeutics • April 22, 2019;  (Issue 1570)
Patients with seasonal allergies often experience nasal itching and congestion, sneezing, rhinorrhea, and itchy, watery eyes. Oral, intranasal, and ophthalmic preparations are widely available over the...
Patients with seasonal allergies often experience nasal itching and congestion, sneezing, rhinorrhea, and itchy, watery eyes. Oral, intranasal, and ophthalmic preparations are widely available over the counter (OTC) for relief of symptoms. Prescription products for management of allergic rhinitis and allergic conjunctivitis are reviewed separately.
Med Lett Drugs Ther. 2019 Apr 22;61(1570):57-60 | Show Full IntroductionHide Full Introduction

Bepotastine (Bepreve) - An Ophthalmic H1-Antihistamine

   
The Medical Letter on Drugs and Therapeutics • February 8, 2010;  (Issue 1331)
Bepotastine besilate 1.5% ophthalmic solution (Bepreve - ISTA Pharmaceuticals), an H1-antihistamine, has been approved by the FDA for topical treatment of itching associated with allergic conjunctivitis in...
Bepotastine besilate 1.5% ophthalmic solution (Bepreve - ISTA Pharmaceuticals), an H1-antihistamine, has been approved by the FDA for topical treatment of itching associated with allergic conjunctivitis in patients ≥2 years old. Bepotastine was first developed in an oral systemic formulation and has been used as such for treatment of allergic rhinitis in Japan.
Med Lett Drugs Ther. 2010 Feb 8;52(1331):11-2 | Show Full IntroductionHide Full Introduction